Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 27Active not recruiting 14Not yet recruiting 7Completed 5Terminated 1Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 128Breast Neoplasms 111Neoplasms 93Neoplasm Metastasis 76Melanoma 70Colorectal Neoplasms 69Leukemia, Myeloid, Acute 66Prostatic Neoplasms 58Multiple Myeloma 52Lung Neoplasms 51Ovarian Neoplasms 49Squamous Cell Carcinoma of Head and Neck 45Recurrence 41Triple Negative Breast Neoplasms 40Carcinoma, Renal Cell 38Carcinoma, Hepatocellular 38Pancreatic Neoplasms 36Myelodysplastic Syndromes 36Glioblastoma 34Brain Neoplasms 34Stomach Neoplasms 30Lymphoma, Non-Hodgkin 30Lymphoma 30Endometrial Neoplasms 30Head and Neck Neoplasms 28Lymphoma, Large B-Cell, Diffuse 27Leukemia 27Uterine Cervical Neoplasms 26Cholangiocarcinoma 26Urinary Bladder Neoplasms 24

Interventions

iadademstat 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Neuroendocrine × 1 year × Clear all
NCT05420636 2025-07-30

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Fox Chase Cancer Center

Phase 2 Terminated
20 enrolled
EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡